Published in J Dtsch Dermatol Ges on May 07, 2008
Immunohistochemical detection of P53 and Mdm2 in vitiligo. Indian Dermatol Online J (2012) 1.06
Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review. Med Oncol (2009) 0.88
Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res (2013) 0.82
Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients? Balkan Med J (2016) 0.75
Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo. Exp Dermatol (2014) 0.75
Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. Br J Dermatol (2016) 0.75
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol (2008) 3.29
Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov (2006) 3.08
Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02
Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol (2010) 2.88
Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer (2009) 2.77
A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med (2002) 2.55
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Split-skin grafting from the scalp: the hidden advantage. Dermatol Surg (2009) 2.08
Quantitation of human seroresponsiveness to Merkel cell polyomavirus. PLoS Pathog (2009) 2.08
B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65
Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther (2004) 1.56
Role of matrix metalloproteinases in melanoma cell invasion. Biochimie (2005) 1.54
Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol (2002) 1.50
The universal character of the tumor-associated antigen survivin. Clin Cancer Res (2007) 1.50
An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer (2011) 1.49
Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother (2007) 1.49
Cytotoxic T cells. J Invest Dermatol (2006) 1.47
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother (2005) 1.47
The etiology and epidemiology of merkel cell carcinoma. Curr Probl Cancer (2010) 1.39
Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res (2009) 1.34
Merkel cell carcinoma: recent insights and new treatment options. Curr Opin Oncol (2012) 1.30
Expression of stress-induced MHC class I related chain molecules on human melanoma. J Invest Dermatol (2002) 1.30
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Bullous allergic hypersensitivity to bed bug bites mediated by IgE against salivary nitrophorin. J Invest Dermatol (2006) 1.24
Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 1.23
Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov (2005) 1.22
Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res (2009) 1.19
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest (2009) 1.19
Postnatal confirmation of prenatally diagnosed trisomy 20 mosaicism in a patient with linear and whorled nevoid hypermelanosis. Pediatr Dermatol (2004) 1.15
Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation. Cancer Res (2003) 1.14
IGFBP7 is not required for B-RAF-induced melanocyte senescence. Cell (2010) 1.13
Immunogenicity of constitutively active V599EBRaf. Cancer Res (2004) 1.12
Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res (2003) 1.12
High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One (2011) 1.11
CD147 impacts angiogenesis and metastasis formation. Cancer Invest (2009) 1.11
Flagellate dermatitis caused by shiitake mushrooms. An Bras Dermatol (2012) 1.10
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Invest Dermatol (2011) 1.06
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine (2005) 1.05
The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations. J Invest Dermatol (2010) 1.04
Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res (2007) 1.04
Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother (2007) 1.04
["Lues maligna" in a female patient with diabetes]. J Dtsch Dermatol Ges (2005) 1.03
TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol (2003) 1.03
Merkel cell polyomavirus-positive Merkel cell carcinoma cells do not require expression of the viral small T antigen. J Invest Dermatol (2013) 1.03
Spontaneous immunity against Bcl-xL in cancer patients. J Immunol (2005) 1.00
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer (2012) 1.00
Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol (2010) 1.00
Type I and II IFNs inhibit Merkel cell carcinoma via modulation of the Merkel cell polyomavirus T antigens. Cancer Res (2012) 0.99
A novel xenograft model of cutaneous T-cell lymphoma. Exp Dermatol (2010) 0.99
Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol (2010) 0.99
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol (2003) 0.99
Profiling chemokines, cytokines and growth factors in human early pregnancy decidua by protein array. Am J Reprod Immunol (2007) 0.99
Interaction of human hematopoietic stem cells with bacterial pathogens. Blood (2002) 0.98
Immunogenicity of Bcl-2 in patients with cancer. Blood (2004) 0.98
Immunoblotting and enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Obstet Gynecol (2004) 0.96
B-Raf specific antibody responses in melanoma patients. BMC Cancer (2004) 0.96
Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res (2009) 0.95
Molecular pathogenesis of Merkel cell carcinoma. Exp Dermatol (2009) 0.95
Childhood psoriasis. Clin Dermatol (2007) 0.94
HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer (2004) 0.94
Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus-positive and negative Merkel cell carcinoma. Int J Cancer (2010) 0.94
Brooke-Spiegler syndrome complicated by unilateral hearing loss. Int J Dermatol (2008) 0.94
The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol (2004) 0.94
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res (2014) 0.94
Transport of Streptococcus pneumoniae capsular polysaccharide in MHC Class II tubules. PLoS Pathog (2007) 0.93
Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol (2002) 0.93
Encephalocraniocutaneous lipomatosis: a case with unilateral odontomas and review of the literature. Eur J Pediatr (2003) 0.92
Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol (2011) 0.92
Cancer treatment: the combination of vaccination with other therapies. Cancer Immunol Immunother (2008) 0.92
Angiolymphoid hyperplasia with eosinophilia and Kimura's disease - a clinical and histopathological comparison. J Dtsch Dermatol Ges (2014) 0.92
T-cell clonotypes in cancer. J Transl Med (2004) 0.91
DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci U S A (2005) 0.89
Imatinib in melanoma: a selective treatment option based on KIT mutation status? J Clin Oncol (2007) 0.89
Tumor stroma-associated antigens for anti-cancer immunotherapy. Cancer Immunol Immunother (2005) 0.88
Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol (2002) 0.88
Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol (2006) 0.88
Merkel cell carcinoma and Merkel cell polyomavirus: evidence for hit-and-run oncogenesis. J Invest Dermatol (2011) 0.88
Tumor biomarkers in melanoma. Cancer Control (2009) 0.87
Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges (2010) 0.87
HLA-B8 association with late-stage melanoma--an immunological lesson? BMC Med (2006) 0.87
Kaposiform hemangioendothelioma with distant lymphangiomatosis without an association to Kasabach-Merritt-Syndrome in a female adult! Vasc Health Risk Manag (2008) 0.87
Mycosis fungoides bullosa: a case report and review of the literature. J Med Case Rep (2010) 0.86
Novel desmoplakin mutation: juvenile biventricular cardiomyopathy with left ventricular non-compaction and acantholytic palmoplantar keratoderma. Clin Res Cardiol (2011) 0.86
No evidence for association of HPyV6 or HPyV7 with different skin cancers. J Invest Dermatol (2011) 0.86
ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. J Invest Dermatol (2011) 0.86
Control of large institutional scabies outbreaks. J Dtsch Dermatol Ges (2012) 0.85
Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15-PGHD/HPGD loss-of-function mutations. Exp Dermatol (2011) 0.85
Hemangiomas of infancy and childhood. J Dtsch Dermatol Ges (2007) 0.85
Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol (2002) 0.85